(Q37249563)

19 August 2017

1 reference

title

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question (English)

1 reference

19 August 2017

1 reference

John F Deeken

1

1 reference

19 August 2017

Rebecca Slack

series ordinal

2

1 reference

19 August 2017

John L Marshall

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

113

1 reference

19 August 2017

7

1 reference

19 August 2017

1502-1510

1 reference

Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications

19 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Clinical pharmacogenetics of irinotecan (CPT-11).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenomics: road to anticancer therapeutics nirvana?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenetics of irinotecan metabolism and transport: an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

"Irinogenetics" and UGT1A: from genotypes to haplotypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenetics and irinotecan therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenomics and colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenetics of irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Role of pharmacogenetics in irinotecan therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Irinogenetics: what is the right star?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23777

7 January 2021

Identifiers

DOI

10.1002/CNCR.23777

1 reference

19 August 2017

1 reference